NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Stellular Bio

Stellular Bio

Private
Watertown, MassachusettsHealthcare & Life Scienceshttps://www.stellularbio.com/

Last Round

Series B

Nov 4, 2021

Total Funding Raised

$170.13M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Stellular Bio is a biotechnology company that develops a platelet-derived regenerative biologic platform aimed at enhancing the treatment of patients with ocular surface disease.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

regenerative medicineplatelet-derived regenerative biologicPRBoff-the-shelf biologicsocular surface diseasedry eye treatmentbiotech therapeuticsSjögren's diseasebiologics manufacturingcell therapyautologous therapy alternativeclinical stage biotechregenerative therapy

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Stellular Bio Comparables

Compare Stellular Bio with similar companies based on industry and business-model similarity.

Stellular Bio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Claris Bio
81%
Pandorum Technologies
77%
Cambium Bio
77%

Stellular Bio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BNov 4, 2021
GrantSep 30, 2019
Series A ExtensionSep 9, 2019
Series AJun 8, 2017
SeedJul 28, 2016
Grant
Apr 1, 2016

Key People

Founding team and executive leadership

Derek Adams

CEO and President

Executive Team

Li Malmberg

Chief Technology Officer (Part-time contract)

Executive Team

Stellular Bio Investors

Notable investors and investment history

Stellular Bio investors
InvestorRounds
Nest.BioSeries A Extension
Public Health Emergency Medical Countermeasures EnterpriseGrant
Oxford FinanceSeries B
Ziff Capital PartnersSeries B, Series A Extension
National Heart, Lung, and Blood InstituteGrant
Vivo CapitalSeries A
K2 HealthVenturesSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 15, 2026

    Monthly visitors increased 46% MoM.

  • Sep 30, 2019

    $56M grant awarded by Public Health Emergency Medical Countermeasures Enterprise.

Stellular Bio Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Stellular Bio Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Stellular Bio's valuation, stock price, and market status.

Firmographic Details

HeadquartersWatertown, Massachusetts
Employee Range11
Year Founded2014
Last FundingNov 4, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.